Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry

PURPOSE: The extent of the survival benefit of augmentation therapy for alpha-1 antitrypsin deficiency (AATD) in individuals with advanced COPD is difficult to define. We performed a retrospective analysis using all available data from the observational registry of individuals with severe deficiency...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Chron Obstruct Pulmon Dis
Egile Nagusiak: Rahaghi, Franck F, Monk, Richard, Ramakrishnan, Viswanathan, Beiko, Tatsiana, Strange, Charlie
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7721109/
https://ncbi.nlm.nih.gov/pubmed/33299307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S263725
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak